Published online before print September 4, 2006, doi: 10.1161/CIRCULATIONAHA.105.601641
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:1185-1192.)
© 2006 American Heart Association, Inc.
Vascular Medicine |
Rheumatoid Arthritis Is Associated With Increased Aortic Pulse-Wave Velocity, Which Is Reduced by Anti–Tumor Necrosis Factor-
Therapy
From the Clinical Pharmacology Unit (K.M.M.-P., A.D.B., S.M.L.W., Y., C.M.M., I.B.W.) and Department of Clinical Medicine (F.C.H., A.F.), University of Cambridge; Department of Radiology (P.W.P.B., S.H.), Addenbrooke’s Hospital; and Trinity College (J.B.), University of Cambridge, Cambridge, United Kingdom.
Correspondence to Dr Ian B. Wilkinson, Clinical Pharmacology Unit, University of Cambridge, Addenbrooke’s Hospital, Box 110, Cambridge CB2 2QQ, United Kingdom. E-mail ibw20{at}cam.ac.uk
Received November 14, 2005; revision received May 23, 2006; accepted June 8, 2006.
Background— Rheumatoid arthritis (RA) is associated with increased cardiovascular risk, which is not explained by traditional cardiovascular risk factors but may be due in part to increased aortic stiffness, an independent predictor of cardiovascular mortality. In the present study, our aim was to establish whether aortic stiffness is increased in RA and to investigate the relationship between inflammation and aortic stiffness. In addition, we tested the hypothesis that aortic stiffness could be reduced with anti–tumor necrosis factor-
(TNF-) therapy.
Methods and Results— Aortic pulse-wave velocity (PWV), augmentation index, and blood pressure were measured in 77 patients with RA and in 142 healthy individuals. Both acute and chronic inflammatory measures and disease activity were determined. The effect of anti-TNF- therapy on PWV and endothelial function was measured in 9 RA patients at 0, 4, and 12 weeks. Median (interquartile range) aortic PWV was significantly higher in subjects with RA than in control subjects (8.35 [7.14 to 10.24] versus 7.52 [6.56 to 9.18] m/s, respectively; P=0.005). In multiple regression analyses, aortic PWV correlated independently with age, mean arterial pressure, and log-transformed C-reactive protein (R2=0.701; P<0.0001). Aortic PWV was reduced significantly by anti-TNF- therapy (8.82±2.04 versus 7.94±1.86 versus 7.68±1.56 m/s at weeks 0, 4, and 12, respectively; P<0.001); concomitantly, endothelial function improved.
Conclusions— RA is associated with increased aortic stiffness, which correlates with current but not historical measures of inflammation, suggesting that increased aortic stiffness may be reversible. Indeed, anti-TNF- therapy reduced aortic stiffness to a level comparable to that of healthy individuals. Therefore, effective control of inflammation may be of benefit in reducing cardiovascular risk in patients with RA.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  M. A. Crilly, V. Kumar, H. J. Clark, N. W. Scott, A. G. MacDonald, and D. J. Williams Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: a dose-response relationship independent of established cardiovascular risk factors Rheumatology, December 1, 2009; 48(12): 1606 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cecelja and P. Chowienczyk Dissociation of Aortic Pulse Wave Velocity With Risk Factors for Cardiovascular Disease Other Than Hypertension: A Systematic Review Hypertension, December 1, 2009; 54(6): 1328 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Galarraga, F. Khan, P. Kumar, T. Pullar, and J. J. F. Belch Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis Rheumatology, November 1, 2009; 48(11): 1418 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. SABIO, J. VARGAS-HITOS, M. ZAMORA-PASADAS, J. D. MEDIAVILLA, N. NAVARRETE, A. RAMIREZ, C. HIDALGO-TENORIO, L. JAIMEZ, J. MARTIN, J. JIMENEZ-ALONSO, et al. Metabolic Syndrome Is Associated with Increased Arterial Stiffness and Biomarkers of Subclinical Atherosclerosis in Patients with Systemic Lupus Erythematosus J Rheumatol, October 1, 2009; 36(10): 2204 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Hamdulay and J. C Mason Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA? Heart, September 15, 2009; 95(18): 1471 - 1472. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Xiong, J. MacTaggart, R. Knispel, J. Worth, Y. Persidsky, and B. T. Baxter Blocking TNF-{alpha} Attenuates Aneurysm Formation in a Murine Model J. Immunol., August 15, 2009; 183(4): 2741 - 2746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Wong, S P Oakley, L Young, B Y Jiang, A Wierzbicki, G Panayi, P Chowienczyk, and B Kirkham Infliximab improves vascular stiffness in patients with rheumatoid arthritis Ann Rheum Dis, August 1, 2009; 68(8): 1277 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E Bolton, J. R Cockcroft, R. Sabit, M. Munnery, C. M McEniery, I. B Wilkinson, S. Ebrahim, J. E Gallacher, D. J Shale, and Y. Ben-Shlomo Lung function in mid-life compared with later life is a stronger predictor of arterial stiffness in men: The Caerphilly Prospective Study Int. J. Epidemiol., June 1, 2009; 38(3): 867 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Cypiene, M Kovaite, A Venalis, J Dadoniene, R Rugiene, Z Petrulioniene, L Ryliskyte, and A Laucevicius Arterial wall dysfunction in systemic lupus erythematosus Lupus, May 1, 2009; 18(6): 522 - 529. [Abstract] [PDF]
|
|
|
|
|
|
F. Montecucco and F. Mach Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis Rheumatology, January 1, 2009; 48(1): 11 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Galarraga, F. Khan, P. Kumar, T. Pullar, and J. J. F. Belch C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis Rheumatology, December 1, 2008; 47(12): 1780 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-f. Cheung, G.-y. Huang, S.-b. Chen, X.-q. Liu, L. Xi, X.-c. Liang, M.-r. Huang, S. Chen, L.-s. Huang, X.-q. Liu, et al. Inflammatory Gene Polymorphisms and Susceptibility to Kawasaki Disease and Its Arterial Sequelae Pediatrics, September 1, 2008; 122(3): e608 - e614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. F. Panoulas, G. S. Metsios, A. V. Pace, H. John, G. J. Treharne, M. J. Banks, and G. D. Kitas Hypertension in rheumatoid arthritis Rheumatology, September 1, 2008; 47(9): 1286 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Wong, M. Freiberg, R. Tracy, and L. Kuller Epidemiology of Cytokines: The Women On the Move through Activity and Nutrition (WOMAN) Study Am. J. Epidemiol., August 15, 2008; 168(4): 443 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schnabel, M. G. Larson, J. Dupuis, K. L. Lunetta, I. Lipinska, J. B. Meigs, X. Yin, J. Rong, J. A. Vita, C. Newton-Cheh, et al. Relations of Inflammatory Biomarkers and Common Genetic Variants With Arterial Stiffness and Wave Reflection Hypertension, June 1, 2008; 51(6): 1651 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ikonomidis, J. P. Lekakis, M. Nikolaou, I. Paraskevaidis, I. Andreadou, T. Kaplanoglou, P. Katsimbri, G. Skarantavos, P. N. Soucacos, and D. T. Kremastinos Inhibition of Interleukin-1 by Anakinra Improves Vascular and Left Ventricular Function in Patients With Rheumatoid Arthritis Circulation, May 20, 2008; 117(20): 2662 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ghiadoni, G. Penno, C. Giannarelli, Y. Plantinga, M. Bernardini, L. Pucci, R. Miccoli, S. Taddei, A. Salvetti, and S. Del Prato Metabolic Syndrome and Vascular Alterations in Normotensive Subjects at Risk of Diabetes Mellitus Hypertension, February 1, 2008; 51(2): 440 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Roman and J. E. Salmon Cardiovascular Manifestations of Rheumatologic Diseases Circulation, November 13, 2007; 116(20): 2346 - 2355. [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Guzik, N. E. Hoch, K. A. Brown, L. A. McCann, A. Rahman, S. Dikalov, J. Goronzy, C. Weyand, and D. G. Harrison Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction J. Exp. Med., October 1, 2007; 204(10): 2449 - 2460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W G Dixon and D P M Symmons What effects might anti-TNF{alpha} treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF{alpha} in cardiovascular pathophysiology Ann Rheum Dis, September 1, 2007; 66(9): 1132 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Maki-Petaja, A. D. Booth, F. C. Hall, S. M.L. Wallace, J. Brown, C. M. McEniery, and I. B. Wilkinson Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis J. Am. Coll. Cardiol., August 28, 2007; 50(9): 852 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Del Porto, B. Lagana, S. Lai, I. Nofroni, F. Tinti, M. Vitale, E. Podesta, A. P. Mitterhofer, and R. D'Amelio Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis Rheumatology, July 1, 2007; 46(7): 1111 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Laurent and P. Boutouyrie Recent Advances in Arterial Stiffness and Wave Reflection in Human Hypertension Hypertension, June 1, 2007; 49(6): 1202 - 1206. [Full Text] [PDF]
|
|
|
|
|
|
A. A. Quyyumi Inflamed Joints and Stiff Arteries: Is Rheumatoid Arthritis a Cardiovascular Risk Factor? Circulation, September 12, 2006; 114(11): 1137 - 1139. [Full Text] [PDF]
|
|